Johnathan Warner, MD
Following the FDA approval of high-intensity focused ultrasound (HIFU) for prostate tissue ablation, there are ongoing clinical trials attempting to determine how effective the technology can be for the treatment of patients with prostate cancer, explains Jonathan Warner, MD.
, Warner, an assistant professor in the Division of Urology and Urologic Oncology, Department of Surgery, City of Hope, discussed the evolving role of surgery and radiation therapy in the treatment landscape for patients with prostate cancer.
OncLive: What are some of the side effects of local definitive therapies for prostate cancer?
If we look at the 2 curative therapies for prostate cancer, radiation and surgery have been the long-term options available for patients. The primary side effects that come with surgery are erectile dysfunction and urinary incontinence. When a patient has surgery and they suffer from one of those consequences, the outcomes and the treatments are very predictable.
With cryotherapy, we see a lot of fistula formations, which are holes between the rectum and the prostate that develop after cryotherapy. Those can be devastating complications with significant risks that are difficult to repair.
Are there ongoing trials with focal therapy looking to further explore the treatment?
There are trials actively ongoing. The biggest change that has happened with focal therapy is the advent of MRI. MRIs have been around for a long time, but the new protocols that are utilized have allowed us to isolate significant lesions found on prostate cancers.
... to read the full story